Autolus Therapeutics PLC (NASDAQ:AUTL)

2.15
Delayed Data
As of Sep 30
 -0.08 / -3.59%
Today’s Change
1.96
Today|||52-Week Range
7.90
-58.57%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$183.6M

Company Description

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Contact Information

Autolus Therapeutics Plc
The Mediaworks
London Greater London W12 7FP
P:442038296230
Investor Relations:

Employees

Shareholders

Mutual fund holders4.15%
Other institutional27.19%
Individual stakeholders--

Top Executives

Christian Martin ItinChief Executive Officer & Director
Christopher VannChief Operating Officer & Senior Vice President
Lucinda CrabtreeChief Financial Officer
Martin PuléChief Scientific Officer & Senior Vice President
David BrochuChief Technical Officer & Senior Vice President